RCP168 is another kind of CXCR4 peptide antagonist that inhibits CXCL12- or MS-5-induced migration of Jurkat or primary CLL cells from patients through down-regulating phosphorylation of Akt and Erk23. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.